Ad Header



The Pulse of the Pharmaceutical Industry

Lonza buys Shire’s U.S. clinical manufacturing site

Written by: | | Dated: Tuesday, October 3rd, 2017


Lonza buys U.S. clinical manufacturing site from Shire


ZURICH (Reuters) – Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

The site in California has a successful regulatory track record and includes single-use bioreactors and associated downstream capabilities, Lonza said. The site employs more than 100 staff who will have the chance to keep working for Lonza, it added.


Reporting by Michael Shields


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation